Roche is fortifying its rDNA interleukin-2 patent position via agreement with Ajinomoto, the Japanese Foundation for Cancer Research, and U.S. research partner, Immunex, in preparation for an upcoming showdown with other biotech firms developing recombinant interleukin-2, the firm indicated in a Nov. 19 press release. Under the agreement with Ajinomoto, Roche is licensing "the rights that will accrue to Ajinomoto as a result of the original cloning in 1982 of the human gene for IL-2 (interleukin-2)," the release notes. With the Ajinomoto agreement, Roche is looking to gain the trump card in future patent disputes over rDNA-derived interleukin-2.Roche expects Ajinomoto to receive a broad patent for its groundbreaking work that covers marketing and manufacturing of recombinant interleukin-2. At present, there are a number of firms with active rDNA-derived interleukin-2 research programs, including Sandoz, Cetus, Biogen, and Collaborative Research. Roche, Biogen, Collaborative Research and Cetus have entered clinicals with recombinant interleukin-2. In taking steps to shore up its interleukin-2 patent position, Roche is anticipating the same kind of patent struggle that is shaping up in the recombinant interferon area. Biogen, Roche's competitor in the race to get alpha-interferon to the market, was issued a broad patent for first cloning the protein last August from the European Patent Office. Roche immediately challenged that patent, maintaining that the Roche/Genentech team was the first to successfully produce the nature protein now used in clinicals. Immunex Clarifies License Agreement With Roche, Settles Dispute With Ajinomoto Ajinomoto, Roche explained, has filed for patent rights to interleukin-2 based on the pioneer work of Dr. Taniguchi, who, while working under a license agreement with Ajinomoto and the Japanese Foundation for Cancer Research in 1982, became the first scientist to clone and publish the genetic sequence for the human IL-2 gene. Roche VP and biotechnology patent law specialist Jon Saxe said his firm believes that, "based on the work of Dr. Taniguchi and his collaborators, Ajinomoto will gain basic patent rights to expression of the human IL-2 gene, to recombinant organisms containing that gene and to recombinant protein." He added: "Gaining the rights to inventions of Taniguchi and his collaborators was considered important for the continuation of our own pioneering clinical work with the protein." Roche rDNA-derived interleukin-2 is currently undergoing clinical testing for AIDS (Acquired Immune Deficiency Syndrome) at the Natl. Institutes of Health. These trials, which began March 1, 1984, "have shown that interleukin-2 is apparently well tolerated at the dosage given," Roche said. The firm added that it "soon" plans "to inaugurate additional trials in AIDS patients as well as in cancer patients whose immune systems have been suppressed by the disease or by chemotherapeutic treatments." In a separate Nov. 19 press release, Immunex noted that a series of interleukin-2 patent agreements were signed between the three firms -- Roche, Ajinomoto, and Immunex. In addition to the Roche/Ajinomoto agreement, under which Roche gets an exclusive license to the Japanese firm's patent position on IL-2 in return for royalties, separate agreements between Roche and Immunex and between Ajinomoto and Immunex have also been concluded. Immunex noted that its agreement with Roche "clarified certain terms of license agreements between Immunex and Roche and its U.S. subsidiary concerning worldwide marketing rights." Under Immunex' agreement with Ajinomoto, the two firms waived rights for claims against each other as a result of the termination of a consulting agreement in 1981.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The UK government has acknowledged that sponsors of clinical trials for rare diseases face challenges around patient recruitment and trial design, which will be addressed in its clinical trials reform, a lawyer says.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Merck’s newly approved Enflonsia for RSV is one of the products expected to be recommended for use by the CDC Advisory Committee on Immunization Practices later this month.
